Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7007725 | 0.95 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL17777824 | 0.87 | DRD2 (0.59) | OPRL1OPRM1CYP3A4HSD17B10SIGMAR1 | |
| SCHEMBL17777787 | 0.85 | SLC6A3 (0.58) | OPRM1SIGMAR1DRD2 | |
| SCHEMBL17777789 | 0.85 | SIGMAR1 (0.59) | OPRK1SIGMAR1DRD4TSHRALDH1A1 | |
| SCHEMBL17777791 | 0.79 | OPRL1 (0.50) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL17767881 | 0.74 | SIGMAR1 (0.49) | OPRL1OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL1777747 | 0.74 | SIGMAR1 (0.81) | SIGMAR1DRD4CYP2C19ALDH1A1POLB | |
| SCHEMBL13952 | 0.74 | SIGMAR1 (0.81) | SIGMAR1DRD4CYP2C19ALDH1A1POLB | |
| SCHEMBL2086761 | 0.74 | TSHR (0.70) | OPRL1CYP3A4HSD17B10SIGMAR1TSHR | |
| Ammonia Solution, Strong SCHEMBL3699405 | 0.72 | SIGMAR1 (0.77) | SIGMAR1DRD4CYP2C19ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022359-B2 | 1,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-07-17 | — | — | US | claimed |
| US-20170354648-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-12-14 | — | — | US | claimed |
| US-10022359-B2 | 1,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-07-17 | — | — | US | disclosed |
| US-10022359-B2 | 1,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-07-17 | — | — | US | disclosed |
| US-10022359-B2 | 1,9-diazaspiro undecane compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-07-17 | — | — | US | disclosed |
| US-20170354648-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-12-14 | — | — | US | disclosed |
| US-20170354648-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-12-14 | — | — | US | disclosed |
| US-20170354648-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-12-14 | — | — | US | disclosed |
| EP-3221315-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016078771-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016078771-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354648-A1 | 1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, SIGMAR1 | OPRL1 5/4885OPRM1 2/4885OPRD1 1/4885 |
| US-10022359-B2 | 1,9-diazaspiro undecane compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | OPRL1 5/4885OPRM1 2/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.